About the Authors

Hilda J. I. de Jong

Affiliations Laboratory for Health Protection Research, National Institute for Public Health and the Environment, Bilthoven, Netherlands, Department of Toxicogenomics, Maastricht University Medical Centre, Maastricht, Netherlands, Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands

Siti R. F. Saldi

Affiliation Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands

Olaf H. Klungel

Affiliation Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands

Rob J. Vandebriel

Affiliation Laboratory for Health Protection Research, National Institute for Public Health and the Environment, Bilthoven, Netherlands

Patrick C. Souverein

Affiliation Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands

Ronald H. B. Meyboom

Affiliations Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands, Uppsala Monitoring Centre, World Health Organisation Collaborating Centre for International Drug Monitoring, Uppsala, Sweden

J. L. M. (Anneke) Passier

Affiliation Netherlands Pharmacovigilance Centre Lareb, ’s-Hertogenbosch, Netherlands

Henk van Loveren

Affiliations Laboratory for Health Protection Research, National Institute for Public Health and the Environment, Bilthoven, Netherlands, Department of Toxicogenomics, Maastricht University Medical Centre, Maastricht, Netherlands

Jan Willem Cohen Tervaert

jw.cohentervaert@maastrichtuniversity.nl

Affiliation Division of Clinical and Experimental Immunology, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, Netherlands

Competing Interests

The Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, employing authors HJI de Jong, SRF Saldi, OH Klungel, PC Souverein and RHB Meyboom has received unrestricted funding for pharmacoepidemiological research from GlaxoSmithKline, Novo Nordisk, private–public funded Top Institute Pharma (www.tipharma.nl and includes co-funding from universities, government and industry) and the Dutch Medicines Evaluation Board. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.

Author Contributions

Contributed to the conception of the study: JWCT. Contributed to the design of the study: HJIdJ SFRS OHK PCS JWCT. Performed the data analysis: HJIdJ SFRS. Drafted the manuscript: HJIdJ. Contributed to the interpretation of the results: OHK RHBM JWCT. Provided the background data for the study: OHK RJV PCS HvL JWCT. Provided the data: RHBM JLMP. Reviewed the manuscript: OHK RJV PCS RHBM JLMP HvL JWCT. Involved in initiating the project to which the study presented belongs: HvL JWCT. Approved of the version to be published: HJIdJ SFRS OHK RJV PCS RHBM JLMP HvL JWCT.